Edesa Free Cash Flow per Share vs Operating Income Analysis
| EDSA Stock | USD 4.40 0.05 1.15% |
Edesa Biotech financial indicator trend analysis is much more than just examining Edesa Biotech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edesa Biotech is a good investment. Please check the relationship between Edesa Biotech Free Cash Flow Per Share and its Operating Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
Free Cash Flow Per Share vs Operating Income
Free Cash Flow per Share vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edesa Biotech Free Cash Flow per Share account and Operating Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Edesa Biotech's Free Cash Flow per Share and Operating Income is -0.35. Overlapping area represents the amount of variation of Free Cash Flow per Share that can explain the historical movement of Operating Income in the same time period over historical financial statements of Edesa Biotech, assuming nothing else is changed. The correlation between historical values of Edesa Biotech's Free Cash Flow per Share and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow per Share of Edesa Biotech are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Free Cash Flow per Share i.e., Edesa Biotech's Free Cash Flow per Share and Operating Income go up and down completely randomly.
Correlation Coefficient | -0.35 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Operating Income
Operating Income is the amount of profit realized from Edesa Biotech operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Edesa Biotech is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Edesa Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 872 M, whereas Selling General Administrative is forecasted to decline to about 3.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 118.2K | 183.5K | 165.1K | 156.9K | Research Development | 13.3M | 4.8M | 5.5M | 4.3M |
Edesa Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Edesa Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edesa Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.8M | 14.6M | 11.6M | 8.9M | 10.2M | 8.7M | |
| Other Current Liab | 1.5M | 1.4M | 2.1M | 1.7M | 2.0M | 1.2M | |
| Total Current Liabilities | 1.5M | 1.5M | 2.1M | 1.8M | 2.1M | 1.3M | |
| Total Stockholder Equity | 6.6M | 13.1M | 9.4M | 7.0M | 8.1M | 6.4M | |
| Net Debt | (7.0M) | (7.7M) | (7.1M) | (5.3M) | (4.7M) | (5.0M) | |
| Retained Earnings | (13.1M) | (26.5M) | (44.0M) | (52.4M) | (47.2M) | (44.8M) | |
| Cash | 7.2M | 7.8M | 7.1M | 5.4M | 6.2M | 5.6M | |
| Non Current Assets Total | 2.7M | 2.5M | 2.5M | 2.5M | 2.8M | 3.0M | |
| Cash And Short Term Investments | 7.2M | 7.8M | 7.1M | 5.4M | 6.2M | 6.8M | |
| Common Stock Shares Outstanding | 8.6M | 12.1M | 16.7M | 20.0M | 23.0M | 24.2M | |
| Liabilities And Stockholders Equity | 10.8M | 14.6M | 11.6M | 8.9M | 10.2M | 8.7M | |
| Other Current Assets | 890.3K | 948.6K | 2.0M | 448.9K | 516.2K | 429.9K | |
| Other Stockholder Equity | 1.3M | 4.7M | 11.2M | 13.0M | 15.0M | 15.7M | |
| Total Liab | 4.1M | 1.5M | 2.2M | 1.8M | 2.1M | 2.3M | |
| Total Current Assets | 8.1M | 12.1M | 9.1M | 6.4M | 7.4M | 7.6M | |
| Property Plant And Equipment Net | 174.8K | 111.6K | 31.2K | 100.1K | 90.1K | 85.6K | |
| Net Receivables | 87.4K | 3.3M | 1.3M | 626.5K | 720.5K | 521.2K | |
| Property Plant And Equipment Gross | 174.8K | 145.4K | 70.7K | 143.9K | 129.5K | 123.1K | |
| Accumulated Other Comprehensive Income | (287.2K) | (205.3K) | (213.6K) | (214.6K) | (193.2K) | (202.8K) | |
| Non Current Liabilities Total | 2.6M | 67.7K | 43.7K | 19.8K | 17.8K | 16.9K | |
| Inventory | 224.3K | (217.1K) | (87.4K) | (1.3M) | (1.1M) | (1.1M) | |
| Common Stock | 18.5M | 34.9M | 42.5M | 46.6M | 53.6M | 39.4M | |
| Property Plant Equipment | 73.1K | 174.8K | 111.6K | 31.2K | 28.0K | 26.6K | |
| Net Tangible Assets | 5.3M | 4.1M | 10.7M | 7.1M | 8.2M | 4.3M | |
| Accounts Payable | 424.6K | 1.5M | 1.4M | 2.1M | 2.4M | 2.6M | |
| Net Invested Capital | 6.6M | 13.1M | 9.4M | 7.0M | 8.1M | 9.4M | |
| Net Working Capital | 6.6M | 10.6M | 7.0M | 4.6M | 4.2M | 5.8M | |
| Capital Stock | 18.5M | 34.9M | 42.5M | 46.6M | 53.6M | 38.7M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Edesa Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Edesa Biotech's short interest history, or implied volatility extrapolated from Edesa Biotech options trading.
Pair Trading with Edesa Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.56) | Return On Equity (0.96) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.